Updated: Merck gives few details on 2024 restructuring plan for manufacturing network
Merck recently approved a restructuring plan for this year, the global pharma announced during its full-year and fourth-quarter earnings report on Thursday.
Although Merck didn’t include details, the restructuring program is meant to “continue the optimization of the company’s Human Health global manufacturing network as the future pipeline shifts to new modalities, and also to optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency,” the company said. The restructuring resulted in charges in its GAAP results of $190 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.